How many insider trades does FilingIQ track for VRDN?

FilingIQ tracks 92 Form 4 insider transactions for VRDN (Viridian Therapeutics, Inc.\DE), covering filings from Sep 21, 2021 onwards. 27 of those were filed in the last 90 days.

Are VRDN insiders net buyers or net sellers?

Across the full Form 4 history for VRDN, 11 transactions (12%) were open-market purchases and 30 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VRDN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is VRDN in?

Viridian Therapeutics, Inc.\DE (VRDN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.76B.

VRDN insider trading

NasdaqCM Healthcare

Viridian Therapeutics, Inc.\DE — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

12% / 33%

Market cap

$2.76B

About Viridian Therapeutics, Inc.\DE

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Company website: www.viridiantherapeutics.com

VRDN insider activity at a glance

FilingIQ has scored 92 insider transactions for VRDN since Sep 21, 2021. The most recent filing in our index is dated May 11, 2026.

Across the full history, 11 open-market purchases and 30 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VRDN insider trades is 59.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VRDN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding VRDN

VR Adviser, LLC

$78.86M · 13.3% of AUM

Avoro Capital Advisors LLC

$46.68M · 0.5% of AUM

Yiheng Capital Management, L.P.

$6.74M · 0.6% of AUM

Frequently asked

How many insider trades does FilingIQ track for VRDN?: FilingIQ tracks 92 Form 4 insider transactions for VRDN (Viridian Therapeutics, Inc.\DE), covering filings from Sep 21, 2021 onwards. 27 of those were filed in the last 90 days.
Are VRDN insiders net buyers or net sellers?: Across the full Form 4 history for VRDN, 11 transactions (12%) were open-market purchases and 30 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VRDN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is VRDN in?: Viridian Therapeutics, Inc.\DE (VRDN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.76B.

Methodology & sources

Every VRDN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.